Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population
Portfolio Pulse from Vandana Singh
Johnson & Johnson's unit Janssen released topline results from the Phase 3 MARIPOSA-2 study evaluating Rybrevant regime versus chemotherapy alone, showing significant improvement in progression-free survival. The study enrolled patients with advanced or metastatic EGFR exon 19 deletions or L858R substitution NSCLC after disease progression on or after AstraZeneca's Tagrisso. JNJ shares are down 1.33% at $158.54.
September 06, 2023 | 6:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Rybrevant shows significant improvement in Phase 3 MARIPOSA-2 study, potentially boosting its market position. However, JNJ shares are currently down 1.33%.
The positive results from the Phase 3 MARIPOSA-2 study could potentially boost Johnson & Johnson's market position in the long run. However, the immediate market reaction seems negative, with JNJ shares down 1.33%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
AstraZeneca's Tagrisso was used as a reference in the Phase 3 MARIPOSA-2 study evaluating Johnson & Johnson's Rybrevant. The impact on AstraZeneca is unclear.
AstraZeneca's Tagrisso was used as a reference in the study, but the news does not provide clear implications for AstraZeneca. Further developments and market reactions need to be monitored.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50